Nico Reinsch1,2, Marina Arendt3, Marie Henrike Geisel3, Christina Schulze4, Volker Holzendorf5, Anna Warnke4, Till Neumann6, Norbert H Brockmeyer7, Dirk Schadendorf4, Lewin Eisele3, Raimund Erbel3, Susanne Moebus3, Karl-Heinz Jöckel3, Stefan Esser4. 1. Department of Internal Medicine I and Cardiology, Division of Electrophysiology, Alfried Krupp von Bohlen and Halbach Hospital, Alfried-Krupp-Str. 21, 45131, Essen, Germany. nico.reinsch@krupp-krankenhaus.de. 2. Department of Cardiology, Witten/Herdecke University, Witten, Germany. nico.reinsch@krupp-krankenhaus.de. 3. Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, Essen, Germany. 4. Clinic of Dermatology, Department of Venerology, University Hospital Essen, Essen, Germany. 5. Clinical Trial Centre Leipzig-Coordination Centre for Clinical Trials (ZKS Leipzig-KKS), University Leipzig, Leipzig, Germany. 6. Out-Patient-Clinic Staubach, Bochum, Germany. 7. Clinic of Dermatology, Venerology and Allergology, Ruhr University Bochum, Bochum, Germany.
Abstract
OBJECTIVES: Prolonged QT interval is associated with arrhythmias and sudden death. An increased prevalence of QT interval prolongation in human immunodeficiency virus-infected (HIV) subjects was previously described. The impact of different medications and HIV infection itself on the QT interval is rarely investigated in large HIV+ cohorts. METHODS: We compared QT interval measurement in 496 HIV(+) patients of the HIV-HEART study (HIVH) and 992 sex- and age-matched controls of the population-based German Heinz Nixdorf Recall study (HNR). QT corrected for heart rate (QTc) >440 ms in male and >460 ms in female was considered pathological. We analysed the impact of HIV status and HIV medication on QTc prolongation in the HIVH subjects. RESULTS: We observed longer QTc in HIVH subjects compared with HNR controls: 424.1 ms ± 23.3 vs. 411.3 ± 15.3 ms for male and 435.5 ms ± 19.6 vs. 416.4 ms ± 17.3 for female subjects (p < 0.0001 for both sexes). Adjusting for QT prolonging medication the mean differences in QTc between the two studies remained significant with 12.6 ms (95% CI 10.5-14.8; p value <0.0001) for male and 19.3 ms (95% CI 14.5-24.2; p value <0.0001) for female subjects. Prolongation of QTc was pathologic in 22.8 vs. 3.9% of HIV(+) and non-infected males and in 12.1 vs. 1.8% of the females [OR of 7.9 (5.0-12.6) and OR of 6.7 (1.8-24.2), respectively]. Smoking behaviour was an independent factor to lengthen QTc in HIV(+) patients. Diabetes mellitus was not a risk factor itself, but might be associated with medication which was associated with LQT. We could not observe any influence of the HIV status, ART, or any co-medication on the QTc. CONCLUSIONS: Our study showed that HIV(+) patients had significantly longer QTc intervals compared to the general population. The number of patients with pathologic QTc prolongation was significantly increased in HIV(+) population.
OBJECTIVES: Prolonged QT interval is associated with arrhythmias and sudden death. An increased prevalence of QT interval prolongation in human immunodeficiency virus-infected (HIV) subjects was previously described. The impact of different medications and HIV infection itself on the QT interval is rarely investigated in large HIV+ cohorts. METHODS: We compared QT interval measurement in 496 HIV(+) patients of the HIV-HEART study (HIVH) and 992 sex- and age-matched controls of the population-based German Heinz Nixdorf Recall study (HNR). QT corrected for heart rate (QTc) >440 ms in male and >460 ms in female was considered pathological. We analysed the impact of HIV status and HIV medication on QTc prolongation in the HIVH subjects. RESULTS: We observed longer QTc in HIVH subjects compared with HNR controls: 424.1 ms ± 23.3 vs. 411.3 ± 15.3 ms for male and 435.5 ms ± 19.6 vs. 416.4 ms ± 17.3 for female subjects (p < 0.0001 for both sexes). Adjusting for QT prolonging medication the mean differences in QTc between the two studies remained significant with 12.6 ms (95% CI 10.5-14.8; p value <0.0001) for male and 19.3 ms (95% CI 14.5-24.2; p value <0.0001) for female subjects. Prolongation of QTc was pathologic in 22.8 vs. 3.9% of HIV(+) and non-infected males and in 12.1 vs. 1.8% of the females [OR of 7.9 (5.0-12.6) and OR of 6.7 (1.8-24.2), respectively]. Smoking behaviour was an independent factor to lengthen QTc in HIV(+) patients. Diabetes mellitus was not a risk factor itself, but might be associated with medication which was associated with LQT. We could not observe any influence of the HIV status, ART, or any co-medication on the QTc. CONCLUSIONS: Our study showed that HIV(+) patients had significantly longer QTc intervals compared to the general population. The number of patients with pathologic QTc prolongation was significantly increased in HIV(+) population.
Authors: Axel Schmermund; Stefan Möhlenkamp; Andreas Stang; Dietrich Grönemeyer; Rainer Seibel; Herbert Hirche; Klaus Mann; Winfried Siffert; Karl Lauterbach; Johannes Siegrist; Karl-Heinz Jöckel; Raimund Erbel Journal: Am Heart J Date: 2002-08 Impact factor: 4.749
Authors: Maartje N Niemeijer; Marten E van den Berg; Jaap W Deckers; Oscar H Franco; Albert Hofman; Jan A Kors; Bruno H Stricker; Peter R Rijnbeek; Mark Eijgelsheim Journal: Heart Rhythm Date: 2015-07-09 Impact factor: 6.343
Authors: Till Neumann; Stefan Esser; Anja Potthoff; Sabine Pankuweit; Anja Neumann; Frank Breuckmann; Katrin Neuhaus; Jana Kondratieva; Thomas Buck; Thomas Müller-Tasch; Rolf Wachter; Christiane Prettin; Götz Gelbrich; Wolfgang Herzog; Burkert Pieske; Mathias Rauchhaus; Markus Löffler; Bernhard Maisch; Andreas Mügge; Jürgen Wasem; Guido Gerken; Norbert H Brockmeyer; Raimund Erbel Journal: Eur J Med Res Date: 2007-06-27 Impact factor: 2.175
Authors: E H Locati; W Zareba; A J Moss; P J Schwartz; G M Vincent; M H Lehmann; J A Towbin; S G Priori; C Napolitano; J L Robinson; M Andrews; K Timothy; W J Hall Journal: Circulation Date: 1998-06-09 Impact factor: 29.690
Authors: J L Willems; C Abreu-Lima; P Arnaud; J H van Bemmel; C Brohet; R Degani; B Denis; J Gehring; I Graham; G van Herpen Journal: N Engl J Med Date: 1991-12-19 Impact factor: 91.245
Authors: Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod Journal: Clin Pharmacokinet Date: 2005 Impact factor: 5.577
Authors: Gerald S Bloomfield; Isabelle R Weir; Heather J Ribaudo; Kathleen V Fitch; Carl J Fichtenbaum; Laura E Moran; Roger Bedimo; Christopher de Filippi; Caryn G Morse; Jonathan Piccini; Markella V Zanni; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Pamela S Douglas Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Sainikitha Prattipati; Francis M Sakita; Tumsifu G Tarimo; Godfrey L Kweka; Jerome J Mlangi; Amedeus V Maro; Lauren A Coaxum; Sophie W Galson; Alexander T Limkakeng; Anzibert Rugakingira; Sarah J Urasa; Nwora L Okeke; Blandina T Mmbaga; Gerald S Bloomfield; Julian T Hertz Journal: Glob Heart Date: 2022-06-10
Authors: Katherine C Wu; Long Zhang; Sabina A Haberlen; Hiroshi Ashikaga; Todd T Brown; Matthew J Budoff; Gypsyamber D'Souza; Lawrence A Kingsley; Frank J Palella; Joseph B Margolick; Otoniel Martínez-Maza; Elsayed Z Soliman; Wendy S Post Journal: Heart Date: 2018-10-26 Impact factor: 5.994
Authors: Geert V T Roozen; Ruchika Meel; Joyce Peper; William D F Venter; Roos E Barth; Diederick E Grobbee; Kerstin Klipstein-Grobusch; Alinda G Vos Journal: PLoS One Date: 2021-02-02 Impact factor: 3.240